2025 H2 -tulosraportti
169 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·10 min sittenMuch positive and exciting around the company currently. Some talk about 8 kr, others about 13 kr etc. That becomes a bit too speculative for my taste. But, please convince me with mathematics and preferably some sentences. PS! AM NOT NEGATIVE..
I bought for 2.89 and sold for 6.2. That is convincing and fun math for my part! Will be a sweet gaming rig! Nah. Will re-enter a bit later this year, after the upcoming "sell the news" wave is over.
·1 t sittenRisk that stop loss will be put to the test today.. Crossing my fingers...
Thor Medical is holding strong today. Already 1.1 million shares have changed hands, so it is clear that some larger players are trading in the market. The stock still shows good interest and is holding up well after the strong rally recently.
·17 t sitten · MuokattuI think Thor has been incredibly strong today considering that we have risen almost 50% in the last 14 days. Normally we would have had a good dip back but I think the expectations are simply too high and too many want to get in for us to fall significantly back. This will be fantastic in the long term😍
Many good comments here. But you are right anyway, Thor is strong as F for the time being. Enjoying this journey to the fullest after the Nano-fuzz long time ago.
·19 t sittenOne thing we can expect after report 28.8 is that new price targets will come. Now everyone knows that the factory is operational. Everyone knows what the production target is (if no new figures are released). So it is possible to calculate revenues and what is needed to come up with a price target. I also feel that some people owe Thor that, without mentioning Dnb with a single word 😉
DNB will probably not issue a significantly higher price target now than they had last time, but hopefully somewhat higher. The reason is precisely that there is nothing new or unexpected on the decision-making table now compared to winter. For example, it was not unknown that the factory would be completed in Q3, nor was there any significant change in the market, approvals, pricing, etc. If DNB were to come with a significantly higher valuation now, they would appear unserious and arbitrary. Then we can agree or disagree with DNB (I disagree), they probably emphasize that the pharmaceutical industry still has not received approved Pb212 medicines. And DNB prices in the lack and uncertainty surrounding these approvals as a risk in Thor.- ·20 t sitten– > What we see here is a classic shift when a company goes from concept to its very first commercial delivery. Such milestones significantly reduce risk, and the trading volume shows that the stock has suddenly landed right in the radar of private investors, says Sundfør to Finansavisen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
169 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 min sittenMuch positive and exciting around the company currently. Some talk about 8 kr, others about 13 kr etc. That becomes a bit too speculative for my taste. But, please convince me with mathematics and preferably some sentences. PS! AM NOT NEGATIVE..I bought for 2.89 and sold for 6.2. That is convincing and fun math for my part! Will be a sweet gaming rig! Nah. Will re-enter a bit later this year, after the upcoming "sell the news" wave is over.
- ·1 t sittenRisk that stop loss will be put to the test today.. Crossing my fingers...Thor Medical is holding strong today. Already 1.1 million shares have changed hands, so it is clear that some larger players are trading in the market. The stock still shows good interest and is holding up well after the strong rally recently.
- ·17 t sitten · MuokattuI think Thor has been incredibly strong today considering that we have risen almost 50% in the last 14 days. Normally we would have had a good dip back but I think the expectations are simply too high and too many want to get in for us to fall significantly back. This will be fantastic in the long term😍Many good comments here. But you are right anyway, Thor is strong as F for the time being. Enjoying this journey to the fullest after the Nano-fuzz long time ago.
- ·19 t sittenOne thing we can expect after report 28.8 is that new price targets will come. Now everyone knows that the factory is operational. Everyone knows what the production target is (if no new figures are released). So it is possible to calculate revenues and what is needed to come up with a price target. I also feel that some people owe Thor that, without mentioning Dnb with a single word 😉DNB will probably not issue a significantly higher price target now than they had last time, but hopefully somewhat higher. The reason is precisely that there is nothing new or unexpected on the decision-making table now compared to winter. For example, it was not unknown that the factory would be completed in Q3, nor was there any significant change in the market, approvals, pricing, etc. If DNB were to come with a significantly higher valuation now, they would appear unserious and arbitrary. Then we can agree or disagree with DNB (I disagree), they probably emphasize that the pharmaceutical industry still has not received approved Pb212 medicines. And DNB prices in the lack and uncertainty surrounding these approvals as a risk in Thor.
- ·20 t sitten– > What we see here is a classic shift when a company goes from concept to its very first commercial delivery. Such milestones significantly reduce risk, and the trading volume shows that the stock has suddenly landed right in the radar of private investors, says Sundfør to Finansavisen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
2025 H2 -tulosraportti
169 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 min sittenMuch positive and exciting around the company currently. Some talk about 8 kr, others about 13 kr etc. That becomes a bit too speculative for my taste. But, please convince me with mathematics and preferably some sentences. PS! AM NOT NEGATIVE..I bought for 2.89 and sold for 6.2. That is convincing and fun math for my part! Will be a sweet gaming rig! Nah. Will re-enter a bit later this year, after the upcoming "sell the news" wave is over.
- ·1 t sittenRisk that stop loss will be put to the test today.. Crossing my fingers...Thor Medical is holding strong today. Already 1.1 million shares have changed hands, so it is clear that some larger players are trading in the market. The stock still shows good interest and is holding up well after the strong rally recently.
- ·17 t sitten · MuokattuI think Thor has been incredibly strong today considering that we have risen almost 50% in the last 14 days. Normally we would have had a good dip back but I think the expectations are simply too high and too many want to get in for us to fall significantly back. This will be fantastic in the long term😍Many good comments here. But you are right anyway, Thor is strong as F for the time being. Enjoying this journey to the fullest after the Nano-fuzz long time ago.
- ·19 t sittenOne thing we can expect after report 28.8 is that new price targets will come. Now everyone knows that the factory is operational. Everyone knows what the production target is (if no new figures are released). So it is possible to calculate revenues and what is needed to come up with a price target. I also feel that some people owe Thor that, without mentioning Dnb with a single word 😉DNB will probably not issue a significantly higher price target now than they had last time, but hopefully somewhat higher. The reason is precisely that there is nothing new or unexpected on the decision-making table now compared to winter. For example, it was not unknown that the factory would be completed in Q3, nor was there any significant change in the market, approvals, pricing, etc. If DNB were to come with a significantly higher valuation now, they would appear unserious and arbitrary. Then we can agree or disagree with DNB (I disagree), they probably emphasize that the pharmaceutical industry still has not received approved Pb212 medicines. And DNB prices in the lack and uncertainty surrounding these approvals as a risk in Thor.
- ·20 t sitten– > What we see here is a classic shift when a company goes from concept to its very first commercial delivery. Such milestones significantly reduce risk, and the trading volume shows that the stock has suddenly landed right in the radar of private investors, says Sundfør to Finansavisen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt